2 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Ayala Pharmaceuticals, Inc,: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Understanding the Burden of ACC Through the Eyes of Patients Adenoid Cystic Carcinoma | Completed | Ayala Pharmaceuticals, Inc, | 46 | 2021-01-11 | 2023-09-29 | |
| A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer AL101 - Triple Negative Breast Cancer | Phase 2 | Terminated | Ayala Pharmaceuticals, Inc, | 18 | 2020-08-14 | 2024-02-12 |
| A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations AL101 - Adenoid Cystic Carcinoma | Phase 2 | Completed | Ayala Pharmaceuticals, Inc, | 87 | 2018-12-14 | 2024-01-31 |
Carcinoma, Adenoid Cystic (2) · Triple Negative Breast Neoplasms (1)
United States (3) · Israel (2) · United Kingdom (2) · Belgium (1) · Canada (1) · France (1) · Netherlands (1) · Spain (1)